Physician profile
Anthony M Auriemma
NPI 1578507562
$788,089.88
in general payments reported to CMS, 2019-2025
26 companies · $187K in 2025
The $187K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $80K · 2021: $97K · 2022: $99K · 2023: $59K · 2024: $173K · 2025: $187K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $249K · Consulting Fee: $105K · Travel and Lodging: $49K · Food and Beverage: $10K · Honoraria: $4,800 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $248,976.39 |
| Consulting Fee | $104,956.50 |
| Travel and Lodging | $49,350.24 |
| Food and Beverage | $10,450.57 |
| Honoraria | $4,800.00 |
| Education | $154.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $467,025.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $145,579.09 | 2020-2025 | Zepbound, Mounjaro |
| Vivus LLC | $98,062.74 | 2019-2025 | Qsymia |
| Currax Pharmaceuticals LLC | $29,898.32 | 2020-2025 | Contrave, Nexletol, Nexlizet |
| Nestle Healthcare Nutrition INC. | $19,957.73 | 2021-2023 | |
| Bausch Health US, LLC | $10,417.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,422.19 | 2025 | |
| Novo Nordisk As | $5,367.06 | 2025 | |
| Eli Lilly and Company | $4,747.40 | 2025 | |
| Kvk-Tech, INC. | $349.42 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $210.02 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.44 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $187.51 | 2021-2024 | Imcivree, Imcivree |
| Corcept Therapeutics | $159.94 | 2024 | Korlym |
| Amarin Pharma, INC. | $123.03 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $121.94 | 2025 | Voquezna |
| Endo Pharmaceuticals INC. | $55.97 | 2019-2022 | |
| Eisai INC. | $39.68 | 2019 | |
| Abbvie INC. | $29.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.68 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $25.74 | 2021 | |
| Boston Scientific Corporation | $20.47 | 2025 | Apollo Esg System |
| Madrigal Pharmaceuticals | $19.67 | 2025 | Rezdiffra |
| Shield Therapeutics INC | $15.75 | 2025 | |
| Esperion Therapeutics, INC. | $13.90 | 2024 | Nexletol |
| Echosens North America, INC. | $4.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Auriemma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.